Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma
Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Listed as NCT01011920, this PHASE2 trial focuses on Central Nervous System Lymphoma and remains completed. Sponsored by International Extranodal Lymphoma Study Group (IELSG), it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- International Extranodal Lymphoma Study Group (IELSG)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Alessandria, Italy , Bellinzona, Switzerland , Brescia, Italy , Erlangen, Germany , Essen, Germany , Freiburg im Breisgau, Germany , Hamburg, Germany , Jena, Germany , Mainz, Germany and 12 more locations